Showing results (1561-1570 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 7, 2007
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II studyEmilio Esteban, Noemi Villanueva, Isabel Muñiz, et al.
Investigational New Drugs|August 1, 1991
Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinomaJ A Ajani, R Pazdur, R J Winn, et al.
Investigational New Drugs|August 1, 1991
Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group studyM L Graham, J Estrada, A H Ragab, et al.
Investigational New Drugs|May 1, 1991
Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065L H Li, R C Kelly, M A Warpehoski, et al.
Investigational New Drugs|May 1, 1991
A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus. A Gynecologic Oncology Group studyR E Slayton, J A Blessing, K Look, et al.
Investigational New Drugs|October 9, 2008
Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cellsAstrid Bernhaus, Maria Ozsvar-Kozma, Philipp Saiko, et al.
Investigational New Drugs|January 9, 2009
A phase I study of an oral simulated FOLFOX with high dose capecitabineD Mulkerin, N K LoConte, K D Holen, et al.
Investigational New Drugs|January 10, 2009
Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase IIAhad A Sadiq, Manish R Patel, Blake A Jacobson, et al.
Investigational New Drugs|October 19, 2007
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecanMurugesan K Gounder, Ahamed S Nazar, Ahamed Saleem, et al.
Investigational New Drugs|October 27, 2007
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trialChristopher W Lee, Karl Bélanger, Sanjay C Rao, et al.
Pageof 372